Novo Nordisk A/S Sponsored ADR (NVO)
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
In the latest trading session, Novo Nordisk (NVO) closed at $38.06, marking a -1.35% move from the previous day.
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium
Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to big pharma peers. NVO trades at ~11.2x 2027 earnings, a ~26% discount to peer median, despite consensus growth rates in line with peers and a robust yield. The investment case does not require a rerating; ~10% annual returns are achievable if current discounted valuations hold and yield continues.
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
Novo Nordisk (NVO) reached $38.26 at the closing of the latest trading day, reflecting a +1.95% change compared to its last close.
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
Eli Lilly obesity drug data adds pressure on Novo Nordisk
Novo Nordisk (NYSE:NVO) faces further pressure in the obesity-drug market after Eli Lilly and Co (NYSE:LLY) reported promising mid-stage data for an experimental treatment that delivered greater weight loss than tirzepatide alone. EloraTZP, a combination of eloralintide and tirzepatide targeting amylin, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways, produced weight loss of up to 23.3% after 48 weeks in overweight or obese patients with type 2 diabetes.
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
People who switched from obesity injections to Novo's new Wegovy pill continued to lose weight after three months, according to an analysis of real-world data the company presented. Patients who switched from either a Wegovy shot or Lilly's Zepbound injection to the Wegovy pill and stayed on treatment for three months lost roughly 4% of their weight on average.
Novo Nordisk: After A 70+% Drop, It's A Great Investment
Novo Nordisk remains a compelling long-term investment despite a 70% share price decline amid GLP-1 competition. NVO's diversified portfolio, robust R&D pipeline, and rare disease milestones support improved 2026 guidance and international sales momentum. Free cash flow yield is set to rise as capex normalizes, with guidance for 7.6 billion USD FCF and a 4.6% dividend yield.
Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
Jiangsu Hengrui Pharmaceuticals , China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S in a deal worth up to $2.6 billion.
